WEIGHT LOSS SPECIALIST – DHA LAHORE
Once-weekly GLP-1 injection for chronic weight management – prescribed after full evaluation in DHA Lahore.
ویگووی (Semaglutide) ہفتے میں ایک بار لگایا جانے والا انجیکشن ہے جو بھوک کم کرتا ہے اور وزن میں مستقل کمی لاتا ہے۔ ڈاکٹر رضوان نیازی مکمل طبی معائنے کے بعد اسے تجویز کرتے ہیں۔
Wegovy is a once-weekly GLP-1 receptor agonist containing Semaglutide at a higher dose specifically approved for chronic weight management. It works by mimicking the GLP-1 hormone, which regulates appetite, food intake, and digestion.
Clinical trials show an average of ~15% body weight reduction over 68 weeks, with improvements in cardiovascular risk, blood pressure, and blood sugar levels.
Semaglutide activates GLP-1 receptors in the brain and gut to regulate hunger, digestion, and blood sugar.
Acts on hunger centres in the brain, reducing appetite and food cravings throughout the day.
Delays gastric emptying so meals are processed more slowly, keeping you fuller for longer.
Improves insulin secretion and reduces glucagon – leading to better blood sugar regulation and metabolic health.
Wegovy is FDA-approved for chronic weight management. A proper clinical assessment is required before starting treatment.
Nausea, vomiting, diarrhoea, and constipation are most common in early weeks. These typically reduce as the body adjusts.
Not recommended for patients with personal or family history of thyroid cancer, pancreatitis, or certain GI conditions. Assessment required.
When correctly prescribed and monitored, Wegovy is safe and effective for medically suitable patients.
Book a consultation with Dr. Rizwan Niazi for a full evaluation and personalised prescription plan.
Dr. Rizwan also prescribes the following injections based on individual patient assessment.
ⓘ All injections are prescribed based on individual assessment under proper medical supervision.
Wegovy must be prescribed and monitored by a qualified specialist. The dose must be carefully titrated, and regular follow-ups are essential for safety and results.
Your BMI, medical history, current medications, and metabolic markers are reviewed before prescribing.
Scheduled reviews allow dose adjustments and ensure progress is on track throughout treatment.
Blood tests track metabolic response and rule out contraindications during the course of treatment.
Wegovy, Mounjaro, Saxenda, and other injections each have different mechanisms and suitability criteria. A consultation helps identify the safest and most effective option for your profile.
Both contain Semaglutide, but Wegovy is approved specifically for weight management at a higher dose (up to 2.4 mg/week), while Ozempic is approved for Type 2 diabetes at lower doses.
Clinical trials show approximately 15% body weight reduction over 68 weeks. Results vary based on dose, diet, lifestyle, and individual response.
Yes. Wegovy (Semaglutide) is available and can be prescribed by a qualified specialist in Pakistan. Dr. Rizwan Niazi prescribes it following a full clinical assessment in DHA Lahore.
Wegovy is a once-weekly subcutaneous injection. The dose starts at 0.25 mg/week and increases gradually to the maintenance dose of 2.4 mg/week over 16–20 weeks.
The most common side effects are nausea, vomiting, diarrhoea, and constipation – especially in the first weeks of treatment. Most patients tolerate the medication well after dose titration.
Yes. Wegovy is a prescription-only medication and must be used under direct medical supervision. A clinical assessment is required before starting treatment.